India's Haemophilia Crisis: 4% Access Preventive Care

A significant portion of India's estimated 140,000 haemophilia patients struggle with inadequate care. Currently, only 4% of those affected can access preventive treatment, a stark contrast to developed nations. This limited access contributes to widespread disability, particularly among children. Families face immense financial and emotional burdens due to recurrent bleeding episodes and the high cost of healthcare.

While newer non-factor therapies (NFTs) offer a promising alternative with fewer infusions and better management of complications, their availability in India is restricted. These advanced treatments, like Emicizumab, are mainly accessible in the private sector and only in select states. Karnataka's recent allocation of ₹42.55 crore for free prophylaxis care highlights a growing, albeit localized, commitment to improving treatment.

The national public health system requires strengthening to ensure equitable access to these life-changing therapies. Establishing national treatment guidelines and expanding the reach of NFTs within the public health framework could dramatically improve the quality of life for India's haemophilic population, aligning with global best practices.